Results 141 to 150 of about 11,092,249 (251)

Teaching AI for Radiology Applications: A Multisociety‑Recommended Syllabus from the AAPM, ACR, RSNA, and SIIM. [PDF]

Med Phys
Kitamura F, Kline T, Warren D, Moy L, Daneshjou R, Maleki F, Santos I, Gichoya J, Wiggins W, Bialecki B, O'Donnell K, Flanders AE, Morgan M, Safdar N, Andriole KP, Geis R, Allen B, Dreyer K, Lungren M, Wood MJ, Kohli M, Langer S, Shih G, Farina E, Kahn CE, Reiser I, Giger M, Wald C, Mongan J, Cook T, Tenenholtz N.   +30 more
europepmc   +1 more source

Exploring the Perceived Value of Standing in Individuals with Lower Limb Impairments. [PDF]

J Clin Med
Shimizu Y, Kadone H, Eguchi Y, Sasaki K, Suzuki K, Hada Y.   +5 more
europepmc   +1 more source

Do Romanian Banking Institutions Create Shareholder Value?

, 2012
Anca Munteanu, Petre Brezeanu
openalex   +1 more source

Tissue Engineered Vascular Grafts: A Quarter Century Journey of Courage, Challenge, and Persistence. [PDF]

JACC Basic Transl Sci
Emmert MY, Generali M, Zilla P, Hoerstrup SP.   +3 more
europepmc   +1 more source

From union clout to corporate couture: Unveiling the impact of trade unions on corporate social responsibility. [PDF]

PLoS One
Mandliya A, Pandey J, Sohani SS, Sheikh RA.   +3 more
europepmc   +1 more source

The impact of mergers and acquisitions on technological innovation in state-owned enterprises: The moderating role of mixed-ownership. [PDF]

PLoS One
Wu N, Guo F, Wang B.
europepmc   +1 more source

Comparative effectiveness of porcine placental extracellular matrix against other cellular, acellular and matrix-like products in diabetic foot ulcers from the Medicare database. [PDF]

J Comp Eff Res
Marcinek B, Levinson J, Nally S, Varghese I, Sheetz C, Kardel P, Taylor C.   +6 more
europepmc   +1 more source

Does Brand Licensing Increase a Licensor's Shareholder Value?

, 2014
Adina B. Robinson, Kapil R. Tuli, Ajay K. Kohli   +2 more
openalex   +2 more sources

Companies Should Maximize Shareholder Welfare Not Market Value

, 2017
Oliver Hart, Luigi Zingales
semanticscholar   +1 more source

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial. [PDF]

Curr Oncol
Yin C, Ethier JL, Carey MS, Tu D, Zheng X.   +4 more
europepmc   +1 more source